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Background: Chronic lymphocytic leukemia (CLL) is a slowly progressing but fatal disease that imposes a high
economic burden on sickness funds and society. The objective of this study was to analyze and compare the direct
and indirect costs of CLL in Germany from the perspective of the sickness funds and society and analyze the
burden of the disease.
Methods: Using a database of 7.6 million enrolled individuals, we identified 4198 CLL patients in 2007 and 2008.
The costs attributable to CLL were estimated using a case–control design with a randomly selected control group
of 150 individuals per combination of age and sex. We used the bootstrap approach to estimate uncertainties in
costs estimated. We employed generalized estimating equation regression models and count data models to test
for differences in costs and healthcare utilization.
Results: The cost attributable to CLL for each prevalent case amounts to €4946 from the payer’s perspective and
€7910 from a societal perspective. Inpatient hospital stays and pharmaceuticals are the main cost drivers of the
disease. The economic burden of disease in Germany was estimated to be approximately €201 million per year for
the sickness funds and €322 million for society.
Conclusions: Compared with common diseases, such as diabetes or COPD, the economic burden of CLL is
considerably lower. However, the cost of treatment per case is about twice as high as the cost per case for these
common diseases, even though treatment is only performed in the later stages of CLL. With new healthcare
technologies, the aging population, and the increasing incidence of the disease, it is likely that the economic
burden of the disease will continue to grow.
Keywords: CLL, Routine data, Administrative data, Economic evaluation, Case–control design, Elixhauser
comorbidity groupsBackground
B-cell chronic lymphocytic leukemia (CLL) is a rare
form of cancer that most often appears in older patients.
The median age at first diagnosis is 64 years, with an
expected survival of more than 10 years [1]. The preva-
lence is estimated to be 3 per 10,000 people [2], with an
incidence of 0.46 per 10,000 people per year [3]. Although
CLL is the most common type of adult leukemia in the
western hemisphere [4,5], it is classified as a rare disease
according to the standards of the EU (where the preva-
lence criterion for a rare disease is set at <5 per 10,000
people) and U.S. (<7.5 per 10,000 people) [6].* Correspondence: rudolf.blankart@wiso.uni-hamburg.de
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reproduction in any medium, provided the orThe vast majority of the literature on CLL compares
different medical treatment options or evaluates comor-
bidities and their influence on the progression of the
disease, but there are few comprehensive cost studies
[5,7]. The literature written from an economic perspec-
tive primarily consists of cost-effectiveness studies that
focus only on the cost differences between pharmaco-
logical treatments. This study provides robust and reli-
able information on the burden of a rare disease from
the sickness fund perspective and societal perspective,
using a large sample of CLL patients. First, we calculated
costs attributable to CLL, defined as difference between
costs of a CLL patient and costs of an average enrolled in-
dividual with the same age and sex. Additionally, cost
differences in various cost categories and indicators forl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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estimating equation regression (GEE) [8] and count data
models. We used the bootstrap approach [9] for uncer-
tainty estimation. In this study, we demonstrated a
sophisticated economic approach to analyzing the burden
of chronic disease using administrative data.
Methods
Study sample and study design
We obtained access to data from the Techniker
Krankenkasse, a large German sickness fund that covers
7.6 million people (i.e., approximately 9% of Germany’s
population in 2008). We collected panel data for two dif-
ferent groups of patients in 2007 and 2008. First, we
selected all enrolled persons who had been given a reli-
able ICD-10 diagnosis of C91.1 (the CLL group). Second,
we randomly selected 150 male and female enrolled
individuals for every year of age between 0 and 100, i.e.,
150 × 2 × 100 individuals. To form the control group,
we selected 150 individuals with the same age and sex
per CLL patient, i.e., we created a control group con-
sisting of 4198 × 150 observations while we used the
age- and sex-specific controls multiple times if one age
and sex group contained more than one prevalent sub-
ject. By comparing the differences between the two
groups, we were able to calculate the costs attributable
to CLL. To be included in our study, all patients were
required to be continuously enrolled in the calendar year
of 2007 or 2008 or in both years, with the exception of
patients who died during the observation period.
The dataset included socio-demographic information
(i.e., age, sex, employment status, entitlement to a regu-
lar or occupational disability pension, etc.) and the direct
medical and non-medical costs to the payer. We also
obtained information on the participants’ inpatient and
outpatient diagnoses, sick-leave days, hospital days,
physician contacts, inpatient stays, and prescriptions
filled.
Measurement of costs from the perspective of the
sickness funds
The direct medical costs included the costs of in- and
outpatient care, pharmaceuticals, nursing care at home,
medical aids, services from non-physicians, and rehabili-
tation. In the absence of specific data on dental costs,
we included the average dental cost across all sickness
funds in Germany for all patients [10]. The direct non-
medical costs reimbursed by sickness funds comprised
the expenses paid for sick leave, travel expenses for
physician visits, and the cost of transporting patients
via ambulance. Administration costs were also included
using the average administrative spending amount across
all sickness funds [11] to increase the generalizability
of results.Measurement of costs from the societal perspective
To calculate the costs from the societal perspective, we
made several adjustments to the data. First, we cal-
culated the indirect costs (i.e., productivity losses)
following the human capital approach [12]. We cal-
culated the productivity losses at the patient level by
multiplying the gross income (adjusted by sex and year
[13]) by the number of sick-leave days. To consider
disease-related unemployment, we corrected our data to
reflect the average proportion of working household
members reported by the federal statistical office.
Second, to better reflect the costs, we considered the
co-payments made by the patients for direct and indirect
medical costs. In our analysis, we included the following
co-payments at the patient level for all participants over
18 years of age: (i) €10 per outpatient consultation with
a physician per quarter, up to a maximum of €40 per
year; (ii) €5 per prescription priced below €50, 10% per
prescription priced above €50 and below €100, and €10
per prescription priced above €100; and (iii) €10 per day
in the hospital. We also took into account that the total
annual co-payment is limited to a maximum of 2% of
the patient’s gross income or in the case of a chronic
disease such as CLL, 1% of gross income. To adjust co-
payments to reflect these limits, we used average wages
adjusted by sex and year [13]. The corrections were
applied proportionally to each category of medical costs.
Third, the pharmaceutical costs were corrected to reflect
the value-added tax (19%), and fourth, the hospital costs
were multiplied by 1.047 to reflect the hospitals’ invest-
ment costs not covered by DRGs [14].
Statistical analysis
First, we calculated annual means for each cost category
and the non-cost indicators for both the CLL and con-
trol groups. We used the bootstrap approach [9] to esti-
mate uncertainties in costs estimated, i.e., we created
1000 datasets by drawing randomly with replacement
from the original dataset. The 2.5 and the 97.5%
quantiles of the bootstrap distribution were used as the
limits of the 95% confidence interval. We then
calculated the total costs attributable to CLL from
sickness fund as well as from societal perspective. Sec-
ond, as most of our data were not normally distributed,
we analyzed the differences in means by using GEE re-
gression models. We employed a correlation matrix with
an autoregressive structure in all our models to control
for correlations due to repeated measurements. We
assumed a gamma distribution and used log-link
function for the analysis of all cost categories. Zero-
truncated gamma models were estimated for all cost
categories where the dependent variable was zero for at
least one observation as the dependent variable must
not be zero in case of gamma-specified regression
Table 1 Baseline characteristics and comorbidities
CLL group Control
group
Mean STD Mean STD p-Value
Baseline characteristics
Age 66.1 (13.2) 66.1 (13.2)
Sex (male = 1) 66.9% 66.9%
Mortality (per calendar year) 4.9% 1.7%
Elixhauser comorbidity
groups
Congestive heart failure 12.7% 10.3% <.001
Cardiac arrhythmias 20.9% 18.4% <.001




Peripheral vascular disorders 13.2% 11.8% <.001
Hypertension uncomplicated 52.6% 53.3% 0.214
Hypertension complicated 9.1% 8.4% 0.032
Paralysis 2.4% 2.1% 0.030
Other neurological disorders 4.5% 4.4% 0.469
Chronic pulmonary disease 23.8% 18.4% <.001
Diabetes uncomplicated 19.5% 18.0% 0.001
Diabetes complicated 8.0% 7.1% 0.003
Hypothyroidism 9.2% 7.6% <.001
Renal failure 10.4% 7.9% <.001




AIDS/HIV 0.2% 0.1% <.001
Lymphoma 27.7% 0.8% <.001







Coagulopathy 11.2% 3.4% <.001
Obesity 9.6% 10.2% 0.062




Blood loss anemia 0.5% 0.4% 0.030
Deficiency anemias 4.5% 2.9% <.001
Alcohol abuse 1.7% 2.2% 0.003
Drug abuse 0.5% 0.4% 0.136
Psychoses 1.0% 0.8% 0.018
Depression 17.3% 13.4% <.001
Elixhauser score 10.0 (10.5) 5.2 (7.9) <.001
CLL Chronic lymphocytic leukemia, STD Standard deviation.
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first we analyze if there is a difference between zero and
non-zero cost using a binary variable and second we
analyze the conditional data using a gamma specified
GEE model. The differences between the indicators for
health care utilization, such as the days in the hospital
or the number of prescriptions, were tested using count
data models. Based on the results of the Vuong test [15],
we considered Poisson or negative binominal regression
models for modeling the number of physician contacts,
the number of inpatient stays, and the number of
prescriptions filled. Sick-leave days were modeled with a
zero-inflated negative binomial regression model (ZINB)
because of excess zeros.
Regarding explanatory variables, we included age and
age-squared, as well as dummy variables for CLL vs.
control, sex, and the 31 Elixhauser comorbidity groups
[16,17], in all our models. We allowed the Elixhauser
comorbidity groups to interact with age and age-squared
because the costs associated with comorbidities might
increase or decrease with age. For example, patients
suffering from diabetes are treated with relatively inex-
pensive drugs during the early stages of the disease in
their younger years; at a more advanced stage of the dis-
ease, they may develop complications and need expen-
sive surgery; and finally, at an older age, diabetes
treatment may be reduced because of other deadly com-
orbidities. In addition, we included the interaction of age
and age-squared with sex. The data were Winsorized at
the upper 0.01% level to account for outliers.
Next, we performed an analysis of the pharmaceuticals
administered. In addition to chemotherapeutic drugs, we
analyzed anti-infective drugs because CLL patients have
an increased risk of contracting bacterial infections due
to the leukemia itself (humoral and cellular immune dys-
function) and immunosuppression treatment [18]. We
differentiated between the drug classes using the Ana-
tomical Therapeutic Chemical Classification System
(ATC), and we evaluated the costs for the following
classes: (i) pharmaceuticals acting on blood and blood-
forming organs (ATC B); (ii) anti-infectives for systemic
use (ATC J); (iii) antineoplastic and immunomodulating
agents (ATC L); (iv) cytostatic drugs individually prepared
in the pharmacy; and (v) other pharmaceuticals. To con-
duct a sensitivity analysis, we performed all calculations
for the years 2007 and 2008 separately as subgroup
analyses.
Because CLL is more common in older individuals but
very young patients are also affected, we expected the
costs of the disease to differ by age group. For example,
healthcare providers may put more effort into treating
younger patients than older patients. However, the
higher costs for these treatments may be counteracted
by the fact that many young CLL patients are in the
Table 2 Indicators for healthcare utilization
CLL group Control group Attributable to CLL





Sick leave days (paid and unpaid days) 7.6 (35.5) 3.1 (19.6) 3.6 4.4 5.2 <.001 (Logit)
<.001 (NB)a
Physician contacts 14.7 (7.5) 9.4 (6.6) 5.1 5.3 5.4 <.001b
Inpatient stays 0.95 (2.10) 0.36 (0.96) 0.54 0.59 0.63 0.007b
Average length of stay (if hospitalized) 9.4 8.8 0.5
Prescriptions 18.2 (19.3) 12.8 (14.4) 5.0 5.4 5.9 <.001a
Average prescription cost 148.2 44.5 103.8
CLL chronic lymphocytic leukemia, STD Standard deviation.
a) Zero-inflated negative binomial specified model; b) Negative binominal specified model.
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expensive treatments, such as chemotherapy or hos-
pitalization. To explore this issue, we calculated the
average costs for different age classes; we grouped
all observed individuals into 5-year age classes (0–5,
6–10, . . ., 96–100) and calculated the average total costs
by age class. We also plotted the mean cost for each age
group and also created a scatter plot of the frequencies of
observations.
Calculation of the economic burden of the disease
We calculated the economic burden of the disease for
Germany by extrapolating our results for the 7.6 million
individuals enrolled at the Techniker Krankenkasse to
the entire German population (81.8 million). To control
for uncertainty, we also calculated the economic burden
using the upper and lower boundaries of the confidence
intervals of the total costs. To account for potential
differences in the prevalence of the disease between our
population and the whole of Germany, we also
calculated the burden of the disease based on the preva-
lence figures we obtained from the literature (i.e., data
from a study by Reis et al. [19], the Orphanet database
[2], and the SEER database of the US National Cancer
Institute [3]).
Results
We identified a total of 4198 patients with CLL in 2007
and 2008. Of these patients, we were able to follow 3321
patients for both years, while 877 patients could be
observed for only one calendar year. This resulted in
7519 observations for our analysis, and based on these
figures, we calculated an average prevalence of 4.9 per
10,000 people for 2007/2008. The baseline char-
acteristics are shown in Table 1. The CLL group and
control group had an average age of 66.1 years (standard
deviation 13.2), and the majority of the patients were
male (66.9%). The youngest CLL patient in the sample
was a one-year-old boy, while the oldest was a 99-year-old
woman. For the CLL group, the mortality rate was 4.88%per year, while the mortality rate was 1.72% in the control
group. Not including common diseases of the elderly (e.g.,
hypertension) or non-cancer-related comorbidities (e.g.,
drug abuse), the patients in the CLL group had signifi-
cantly more comorbidities across all of the Elixhauser
comorbidity groups. Similarly, the Elixhauser score was
10.0 for the CLL group and therefore significantly higher
(p < 0.001) than the score of 5.2 for the control group.
Healthcare utilization differed significantly between
the CLL group and control group (Table 2). We found
that on average, the CLL patients were absent from work
for 7.6 days, while the individuals in the control group
spent 3.1 days on sick leave. The CLL patients contacted
a physician significantly more often (p < 0.001), stayed in
the hospital more often (p < 0.001), and received drug
prescriptions more often (p < 0.001) than their age- and
sex-adjusted counterparts.
The costs for various categories of expenses from the
sickness fund perspective and societal perspective are
presented in Table 3. The total average cost for a CLL
patient was €9753 per year, compared with €4807 for a
control group participant of the same age and sex. The
total average costs between the CLL patients and the
control group differed significantly (p < 0.001). The add-
itional cost of CLL thus amounted to €4946 for each pa-
tient. After performing the bootstrap, we identified a
95%-percentile interval of €4612 to €5499 for total costs
attributable to CLL from sickness fund perspective. The
costs of inpatient care and pharmaceuticals were the
main drivers of direct medical costs for CLL patients,
amounting to €3453 and €2699, respectively. The
pharmaceutical costs for CLL patients were approxi-
mately five-fold higher than those for the control group.
However, the proportion of CLL patients that get
pharmaceuticals prescribed does not differ from the
control group (p = 0.816), but the pharmaceutical costs
per year were significantly higher (p < 0.001) if phar-
maceuticals were prescribed. Chemotherapy drugs (i.e.,
antineoplastic and immunomodulating agents) (€835),
cytostatic drugs individually prepared in the pharmacy
Table 3 Average costs per person per year from the sickness fund perspective and societal perspective
Sickness fund perspective Societal perspective
CLL group Control group Costs attributable to CLL CLL group Control group Costs attributable to CLL















€9331 (19,795) €4533 (15,085) €4365 €4798 €5233 <.001a €9221 (19,569) €4617 (15,080) €4173 €4604 €5038 <.001a
Outpatient cost €1699 (3748) €1246 (4304) €370 €453 €544 0.873 (Logit)
<.001 (Gamma)b
€1735 (3747) €1281 (4305) €372 €455 €545 0.545 (Logit)
<.001 (Gamma)b
Inpatient cost €3453 (11,793) €1109 (4178) €2069 €2344 €2602 <.001 (Logit)
0.267 (Gamma)b
€3663 (12,399) €1185 (4425) €2190 €2478 €2750 <.001 (Logit)
0.156 (Gamma)b
Pharmaceuticals €2699 (7469) €568 (1989) €1963 €2131 €2297 0.816 (Logit)
<.001 (Gamma)b
€2342 (6308) €541 (1699) €1659 €1801 €1941 0.843 (Logit)
<.001 (Gamma)b
Nursing care (at home) €858 (9951) €1035 (11,822) -€382 -€177 €52 0.104 (Logit)
0.900 (Gamma)b
€858 (9951) €1035 (11,822) -€382 -€177 €52 0.104 (Logit)
0.900 (Gamma)b
Dentistry €156 (0) €156 (0) €0 €156 (0) €156 (0) €0
Other €466 (2111) €418 (2082) €4 €48 €98 0.508 (Logit)
0.813 (Gamma)b
€466 (2111) €418 (2082) €4 €48 €98 0.508 (Logit)
0.813 (Gamma)b
Direct non-medical costs €231 (1558) €84 (754) €113 €147 €191 <.001 (Logit)
0.116 (Gamma)b
€117 (759) €58 (476) €44 €59 €78 <.001 (Logit)
0.923 (Gamma)b
Sick pay €114 (1340) €26 (576) €60 €88 €121 0.039 (Logit)
0.072 (Gamma)b
€0 €0 €0
Other €117 (759) €58 (476) €44 €59 €78 <.001 (Logit)
0.923 (Gamma)b
€117 (759) €58 (476) €44 €59 €78 <.001 (Logit)
0.923 (Gamma)b
Administration €191 (0) €191 (0) €0 €191 (0) €191 (0) €0
Indirect cost €0 €0 €0 €4410 (8233) €1164 (4546) €3073 €3246 €3400 0.009 (Logit)
<.001 (Gamma)b
Total cost €9753 (20,199) €4807 (15,219) €4612 €4946 €5499 <.001a €13,939 (22,516) €6030 (16,037) €7434 €7910 €8392 <.001a
CLL Chronic lymphocytic leukemia, STD Standard deviation.



















Table 4 Pharmaceutical costs per year by therapeutic
class
CLL group Control group
Costs per year Mean STD Mean STD
ATC B - Blood and blood forming
organs
€143 (1123) €42 (545)
ATC J - Anti-infectives for systemic use €517 (2955) €21 (396)
ATC L - Antineoplastic and
immunomodulating agents
€835 (4906) €77 (1063)
Cytostatic drugs €504 (2392) €41 (835)
Other €700 (2348) €386 (996)
Total pharmaceuticals costs €2699 (7469) €568 (1980)
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represented the largest fractions of pharmaceutical costs
(see Table 4). Inpatient costs of CLL patients and control
group did not significantly differ (p = 0.267) if they were
hospitalized. However, CLL patients had a higher risk to
have at least one inpatient stay per year (p < 0.001). The
proportion of CLL patients that did contact an out-
patient physician did not differ from the control
group (p = 0.873). However, those patients that do
visit an outpatient physician were significantly more
costly (p < 0.001). The economic burden of the disease
for the sickness funds in Germany was estimated to
be €201 million per year with a confidence interval
between €187.6 and €223.6 million. Depending on the
prevalence assumptions used for the calculations, the
economic burden from the point of view of the sickness
funds varied between €122.0 and €201.1 million per year
(see Table 5).
The average costs for various cost categories per year
by age from the sickness fund perspective are shown in
Figure 1. The scatter plot below the cost plot represents
the frequency of observations. As the frequency was low
for patients younger than 35 or older than 85 years of
age, we considered the costs per age class to be reliable
only for the age groups between 35 and 85. The average
yearly cost for each CLL patient from the sickness fund
perspective decreased with increasing age until the age
of 60–65 and thereafter increased again. The additional
cost burden of caring for CLL patients compared with
the control group peaked between the ages of 35 and 40.
From the societal perspective, the total annual cost for
a CLL patient amounted to an average of €13,939
compared with €6030 for an individual in the control
group. The additional cost of CLL thus amounted to
€7910 per patient. After performing the bootstrap, we
identified a 95%-percentile interval of €7434 to €8392
for total costs attributable to CLL from societal perspec-
tive. The main cost drivers were indirect costs,
amounting to €4410 for CLL patients and €1164 for the
control group. The economic burden of the diseaseamounted to €321.7 million for Germany, with €189.7
million in direct costs and €132.0 million in indirect
costs. The confidence interval was estimated to be be-
tween €302.3 and €341.3 million. Depending on the
prevalence assumptions used for the calculations, the
economic burden from the societal perspective varied
between €195.1 and €321.7 million per year (Table 5).
Discussion
In this study, we presented detailed cost data for CLL in
Germany and data on the economic burden of the dis-
ease. We compared the costs of a large sample of CLL
patients with a randomly drawn sample, consisting of
150 individuals per CLL patient, selected by age and sex.
The detailed cost data from the payer perspective and
societal perspective complement existing studies on the
treatment of CLL and cost-effectiveness analyses of dif-
ferent chemotherapy drugs.
Cost of illness was analyzed using a matched control,
prevalence-based approach. The matched control ap-
proach achieves that disease specific costs are isolated
by subtracting out the costs of matched patients and it
provides more accurate estimates compared to methods
that sum all medical or diagnosis specific costs [20].
Application of a regression method was not considered
to be feasible as our analysis is primarily based on ad-
ministrative data. Administrative data does not allow
controlling for unobservable differences, such as genetic
factors that contribute to the etiology of CLL [21], and
therefore regression analysis would lead to biased results
[20]. The prevalence-based approach was considered ap-
propriate to represent the total current economic bur-
den of CLL [22,23].
Compared with earlier findings [2,3], we identified a
considerably higher prevalence of 4.9 per 10,000
individuals. Considering that the EU threshold for a rare
disease is set at 5 per 10,000 individuals, CLL is,
according to our sample, just below the threshold of a
rare disease, but it is much more prevalent than the 3.47
per 10,000 reported by the US National Cancer Institute
[3] or the 3.0 per 10,000 reported by Orphanet [2]. How-
ever, the data from Reis et al. suggest a similar preva-
lence of 4.5 per 10,000 people (861 CLL patients in a
database of 1.9 million individuals) in Germany. The
estimated prevalence has a substantial impact on the es-
timation of the economic burden of the disease. Taking
into account that CLL progresses slowly and is
diagnosed late, the prevalence figures we have presented
may be underestimated because of the potentially high
number of non-diagnosed cases.
From the sickness fund perspective, the costs attribut-
able to CLL for a single patient were €4946, using an
average patient of the same age and sex for comparison.












Figure 1 Total annual costs for the CLL group and control group by age.
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data, an average CLL patient had 0.95 hospital stays per
year, with an average stay of 9.4 days, while we found
0.36 inpatient stays with an average length of 8.8 days in
the control group. Therefore, an average CLL patient
stayed in the hospital 8.9 days per year, compared with
3.0 days in the control group, for a total of 5.9 hospital
days per patient per year attributable to CLL. Interest-
ingly, Reis et al. reported that an average lymphoma pa-
tient spends 27 days (attributable to their disease) in the
hospital per year, with an average cost per day of €139
[19]. In addition, they reported attributable inpatient
costs of approximately €2000 for an average CLL patient,
which is equivalent to 14.4 hospital days, if hospital days
are re-calculated based on the average hospital costs per
day for lymphoma patients reported in their study.
While the inpatient costs are comparable to our finding
of €2344, the length of inpatient stays is much higher.
Therefore, hospital costs per day seem to have increased
substantially since 2000, while the average length of in-
patient stay has decreased. This change may have been













3.00 €113.8 m €122.0 m
Reis et al.1 2000 Germany 4.53
Reis et al.
(adj.)2
2007/2008 Germany 4.53 €171.8 m €184.3 m
SEER
database2
2008 USA 3.47 €131.6 m €141.1 m
1) as reported by Reis et al. (2006); 2) calculated based cost data of this study.system from per diem amounts to reimbursement for
each case (i.e., DRGs) and improvements in healthcare
technology [24]. New healthcare technologies may have
increased costs but reduced the length of stay.
Regarding the economic burden of CLL on society,
our results are comparable to the findings of Reis et al.
(€321.7 million (our study) vs. €314 million (Reis et al.)).
However, we calculated lower direct costs (€189.7
million vs. €262.0 million) and higher indirect costs
(€132.0 million vs. €52 million). Regarding these differ-
ent results, it should be mentioned that the costs
calculated by Reis et al. are based on the year 2000 and
are not discounted. Second, as mentioned above, there
have been major changes in the reimbursement system,
especially in the inpatient sector, that most likely led to
a reduction in the length of stay. This development may
have compensated for the increases in inpatient costs
due to new health technologies. Third, advances in
healthcare technology in the area of pharmaceutical care,
such as chemotherapeutic drugs, have increased costs.
Compared with the results from Reis et al., we found














€223.6 m €189.7 m €132.0 m €302.3 m €321.7 m €341.3 m
€135.6 m €115.0 m €80.1 m €183.4 m €195.1 m €207.0 m
€262.0 m €52.0 m €314.0 m
€204.9 m €173.7 m €121.0 m €277.0 m €294.7 m €312.7 m
€156.9 m €133.1 m €92.6 m €212.1 m €225.7 m €239.5 m
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for the treatment of CLL, have more than tripled since
2000 [25,26].
The costs for an average CLL patient decrease until
the age of 65 and increase again with advancing age,
while the costs for the control group increase steadily
until the age of 85. Accordingly, the difference in the
cost of CLL compared with the control group decreases
to zero at 85. One possible reason is that costly
procedures, such as stem cell transplantation, are used
only for patients under the age of 66. In addition, sick
pay is only paid for employed patients, who are mainly
individuals under the age of 65. With increasing age, the
cost curve of the control group asymptotically converges
with that of CLL patients due to age-related
comorbidities. Bearing in mind that CLL is a slow-
progressing disease, we conclude that younger patients
are more extensively treated for CLL to increase their
chances of survival, while the treatment effort attribut-
able to CLL is reduced for older patients because CLL
might not decrease survival for these patients.
In comparison with other chronic diseases, the overall
economic burden of CLL is low. Although we have to
consider that a comparison of cost of illness studies is
subject to limitations, especially if different methods are
used [20,22], a discussion with the cost of common
diseases is helpful in interpreting the results. Widespread
and common chronic diseases, such as diabetes (€22,288
million in 2001 [27]) and cardiovascular disease (€11,048
million in 2003 [28]), are among the most expensive
diseases in Germany. As CLL is a rare disease, its burden
is approximately 1.4% of the burden of diabetes. How-
ever, the prevalence of CLL is 0.71% of the prevalence of
diabetes, indicating twice the level of spending per
prevalent CLL case. Nevertheless, the costs per prevalent
CLL case are lower than those for cancers of other sites,
such as lung cancer (US$19,196 per prevalent case,
approx. €18,011), prostate cancer (US$8250, approx.
€7741), or ‘other cancer sites’ (US$12,131, approx.
€11,382), reported by Yu et al. for the year 1999 [29]. Be-
cause cancers of these sites progress more rapidly than
CLL, this finding is unsurprising. However, while the
treatment costs in Binet ‘stage 1’ (watch and wait) might
be considerably lower, the costs in later stages might ex-
ceed those of lung or prostate cancer.
Limitations
This study is based on administrative data. Administra-
tive data have the advantage of providing a holistic over-
view of an entire population, covering all outpatient and
inpatient care [30]. It is, however, data collected only for
reimbursement purposes. Therefore, administrative data
lack certain important clinical data (e.g., tumor stage).
Considering the typical progression of the disease, it islikely that the costs for CLL differ substantially by stage.
Therefore, further research may focus on evaluating CLL
costs at various stages of the disease.
When compared with the average sick pay reimbursed
by a CLL patient’s sickness fund per year (€114), the
productivity losses calculated with the human capital
approach (€4410) may still be underestimated because
the sickness fund pays only after six weeks of sick leave,
while the first six weeks are paid by the employer. Thus,
not every claim for being unable to work will be
recorded in the sickness funds’ databases. Although this
affects both groups, it causes a greater downward bias
for the total indirect costs of CLL than the control
group.
Another limitation arises from the use of annual cost
as response variable in the regression models. As mortal-
ity of CLL patients is substantially higher compared to
the control group, costs analyzed are biased downward
by insured living less than 365 days. However, as
healthcare costs are also increased by proximity to death
[31], the overall effect of death, which we cannot control
for, is lessened.
Assessing uncertainty in cost of illness studies is of
particular importance. Within this study we use the
bootstrap approach to account for uncertainty. Other
approaches, such as the Cholesky decomposition
method or the error propagation law, deliver similar
results [32]. However, uncertainty assessed only refers to
stochastic uncertainty. Although we assessed the impact
of different prevalence assumptions on the burden of
disease, we cannot account for other causes of uncer-
tainty, such as systematic upcoding [33].Conclusions
Our results showed that CLL imposes a high economic
burden primarily driven by inpatient and pharmaceutical
costs. From the societal perspective, the highest costs
arise from productivity losses. The substantial increase
in pharmaceutical costs compared with previous studies
and the shift to shorter hospital stays [19] are attribut-
able to the rapid emergence of new healthcare technolo-
gies in the treatment of CLL. With higher survival rates
because of new healthcare technologies, as well as an
aging population and the increasing incidence indicated
by SEER data [3], it is likely that the economic burden of
the disease will continue to increase in the future.Competing interests
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